Multi-center, Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE™) Selinexor (KPT-330) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)

Trial Profile

Multi-center, Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE™) Selinexor (KPT-330) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 23 Mar 2016 Status changed from active, no longer recruiting to discontinued due to enrollment challenges and not as a consequence of any safety concern as reported by ClinicalTrials.gov.
    • 15 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Jun 2015 Planned number of patients changed from 30 to 60 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top